Bollard Group LLC reduced its position in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 1.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,675,081 shares of the medical equipment provider’s stock after selling 432,545 shares during the quarter. Boston Scientific comprises about 43.6% of Bollard Group LLC’s portfolio, making the stock its biggest position. Bollard Group LLC owned 1.62% of Boston Scientific worth $1,280,585,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Fiduciary Alliance LLC purchased a new position in Boston Scientific during the 2nd quarter worth $25,000. BDO Wealth Advisors LLC boosted its position in Boston Scientific by 209.4% during the 2nd quarter. BDO Wealth Advisors LLC now owns 594 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 402 shares in the last quarter. Nemes Rush Group LLC bought a new stake in Boston Scientific during the 2nd quarter valued at $33,000. Sunbelt Securities Inc. bought a new stake in Boston Scientific during the 1st quarter valued at $32,000. Finally, Carolinas Wealth Consulting LLC boosted its position in Boston Scientific by 2,174.2% during the 2nd quarter. Carolinas Wealth Consulting LLC now owns 705 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 674 shares in the last quarter. 89.11% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of BSX opened at $54.95 on Monday. The stock has a 50-day moving average of $52.69 and a two-hundred day moving average of $52.55. The stock has a market cap of $80.50 billion, a P/E ratio of 67.01, a P/E/G ratio of 2.19 and a beta of 0.78. Boston Scientific Co. has a one year low of $44.35 and a one year high of $56.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.90 and a current ratio of 1.42.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.02. The business had revenue of $3.53 billion during the quarter, compared to analyst estimates of $3.48 billion. Boston Scientific had a return on equity of 15.46% and a net margin of 8.93%. The company’s revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the business posted $0.43 EPS. As a group, research analysts predict that Boston Scientific Co. will post 2.01 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 11,671 shares of Boston Scientific stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $53.95, for a total transaction of $629,650.45. Following the completion of the transaction, the executive vice president now owns 57,058 shares in the company, valued at approximately $3,078,279.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Wendy Carruthers sold 11,671 shares of Boston Scientific stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $53.95, for a total value of $629,650.45. Following the completion of the transaction, the executive vice president now owns 57,058 shares in the company, valued at approximately $3,078,279.10. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 113,356 shares of Boston Scientific stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $52.51, for a total value of $5,952,323.56. Following the completion of the transaction, the chief executive officer now owns 1,498,922 shares of the company’s stock, valued at approximately $78,708,394.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 379,628 shares of company stock worth $20,070,814. Insiders own 0.71% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of several recent research reports. UBS Group increased their target price on Boston Scientific from $63.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, September 21st. Morgan Stanley increased their target price on Boston Scientific from $58.00 to $61.00 and gave the company an “overweight” rating in a research report on Monday, December 4th. Barclays increased their target price on Boston Scientific from $59.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, September 22nd. Needham & Company LLC lowered their price objective on Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, October 27th. Finally, Stifel Nicolaus raised their price objective on Boston Scientific from $58.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, September 21st. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $60.70.

Read Our Latest Report on Boston Scientific

Boston Scientific Company Profile (Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Boston Scientific, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Boston Scientific wasn’t on the list.

While Boston Scientific currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Original: MarketBeat News Feed: Boston Scientific Co. (NYSE:BSX) Stake Reduced by Bollard Group LLC